Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenytoin is a small molecule antiepileptic drug of the hydantoin class, primarily used to manage and prevent seizures such as generalized tonic-clonic (grand mal) seizures, complex partial seizures, and to prevent and treat seizures during or after neurosurgery. Its mechanism of action involves voltage-dependent blockade of voltage-gated sodium channels in neurons. By binding preferentially to the inactive state of these channels, phenytoin inhibits sustained high-frequency repetitive firing of action potentials. This stabilizes neuronal membranes and elevates the seizure threshold by reducing post-tetanic potentiation at synapses in the motor cortex, thereby preventing seizure activity from spreading[2][3][4][5][6]. Phenytoin was first introduced in 1946.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenytoin.